You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Cost recovery implementation statement, V1.6

Version 1.6 February 2019

5 February 2019

Book pagination

Appendix 1 - Financial performance by industry sector group

1. Prescription medicines

Volumes[5] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Biological prescription medicines 580 501 764 702 702
Non-biological prescription medicines - higher charge 522 522 628 480 480
Non-biological prescription medicines - lower charge 6,536 5,888 6,523 6,250 6,250
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 71.7 68.5 72.9 77.7 79.7
Total A 71.7 68.5 72.9 77.7 79.7
B: Expenses[6]
Direct 36.9 40.0 39.4 47.7 48.9
Indirect 26.3 28.3 28.8 28.7 29.4
Total B 63.2 68.4 68.2 76.4 78.4
Surplus (deficit) 8.5 0.1 4.7 1.3 1.3

Footnotes


2. Over the counter medicines

Volumes[7] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Over the counter medicines 2,667 2,441 2,687 2,587 2,587
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 6.7 7.8 9.0 9.8 10.0
Total A 6.7 7.8 9.0 9.8 10.0
B: Expenses[8]
Direct 2.8 3.0 2.9 4.2 4.3
Indirect 2.3 2.6 2.4 2.7 2.8
Total B 5.1 5.7 5.3 6.9 7.1
Surplus (deficit) 1.6 2.2 3.7 2.9 3.0

Footnotes


3. Complementary medicines

Volumes[9] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Registered complementary medicines 132 131 128 124 124
Listed complementary medicines 11,003 10,052 10,801 11,132 11,132
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 15.7 13.8 14.5 17.4 17.8
Total A 15.7 13.8 14.5 17.4 17.8
B: Expenses[10]
Direct 7.2 7.3 6.9 10.4 10.7
Indirect 5.2 5.6 5.3 7.4 7.6
Total B 12.4 12.9 12.1 17.9 18.3
Surplus (deficit) 3.3 0.9 2.4 (0.5) (0.4)

Footnotes


4. Medical devices, including in-vitro diagnostic (IVD) devices

Volumes[11] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Included medical devices 44,878 45,267 49,311 41,925 41,925
IVD medical devices N/A N/A 2,452 2,377 2,377
Other therapeutic goods 359 294 293 116 116
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 34.3 37.2 40.6 42.0 43.1
Total A 34.3 37.2 40.6 42.0 43.1
B: Expenses[12]
Direct 17.1 19.6 20.6 25.0 25.6
Indirect 12.2 13.8 16.9 16.5 16.9
Total B 29.4 33.3 37.6 41.5 42.6
Surplus (deficit) 4.9 3.9 3.0 0.5 0.5

Footnotes


5. Good manufacturing practices

Volumes[13] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Low level GMP licence 105 112 111 283* 283*
High level GMP licence 163 163 179 - -

*From 1 July 2018, the low level and high level fees have replaced with single annual licence fee, GMP Annual Licence.

Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 11.2 9.9 13.2 11.4 11.7
Total A 11.2 9.9 13.2 11.4 11.7
B: Expenses[14]
Direct 7.8 8.7 8.8 8.8 9.0
Indirect 5.4 5.7 6.2 5.4 5.5
Total B 13.2 14.4 14.9 14.2 14.6
Surplus (deficit) (2.0) (4.4) (1.7) (2.8) (2.9)

Footnotes


6. Blood, blood components and biologicals

Volumes[15] 2015-16
Actual
2016-17
Actual
2017-18
Actual
2018-19
Budget
2019-20
Estimate
Blood primary site 5 5 5 5 6
Blood secondary site 79 81 78 76 76
Single step manufacturer of human tissue 24 18 17 16 16
Class 2 biological products 20 20 20 20 20
Class 3 biological products 5 6 6 6 6
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 2.2 2.6 2.4 3.1 3.2
Total A 2.2 2.6 2.4 3.1 3.2
B: Expenses[16]
Direct 1.6 2.0 2.0 2.6 2.7
Indirect 1.3 1.6 1.7 1.6 1.6
Total B 2.9 3.6 3.6 4.2 4.3
Surplus (deficit) (0.6) (0.9) (1.3) (1.1) (1.1)

Footnotes


7. Other activities (such as laboratory, medicines and chemical scheduling etc.)

Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Actual
$'m
2018-19
Budget
$'m
2019-20
Estimate
$'m
A: Revenue
Revenue 2.0 1.7 2.7 2.0 2.1
Total A 2.0 1.7 2.7 2.0 2.1
B: Expenses
Other Expense 2.0 2.7 2.6 2.3 2.4
MMDR Expense N/A 6.9 4.1 N/A N/A
Total B 2.0 8.6 6.7 2.3 2.4
Surplus (deficit) 0.0 (6.9) (4.0) (0.3) (0.3)

Book pagination